endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels.

Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners UNITAID and the Transformational Investment Capacity (TIC) of MSF. 

You can contact us, or follow us on Twitter.

Watch the two-minute animation

endTB clinical trial results - VIDEO

The endTB clinical trial results are out! This landmark trial offers multiple new shortened, all-oral drug regimens to treat adults and children with MDR-TB. 

The video is now also available with Spanish, French and Russian subtitles.

Read our press release and more here: https://endtb.org/endtb-clinical-trial-results 

endTB: Ministry of Health of Peru implements shortened treatment against tuberculosis

endTB Peru

April 12, 2024

Socios En Salud is part of a global consortium that managed to shorten the treatment for patients with multidrug-resistant tuberculosis to nine months and without the use of injectables.

Read more here

PIH MSF MSF Unitaid: Save Lives Faster Médecins Sans Frontières (MSF) Transformational Investment Capacity (TIC) logo